Rossari Biotech debuts at Rs 670 with 58% premium over IPO price

The exchange has fixed a 20 percent upper and lower circuit limit at Rs 804 and Rs 536 respectively, over its opening price of Rs 670.

On the National Stock Exchange, the share price traded at Rs 676.75, up by Rs 251.75 or 59.24 percent over IPO price, with volumes of 40,88,564 equity shares.

The Rs 496-crore initial public offering of Rossari Biotech had seen a hefty subscription of 79.37 times during July 13-15.

The public issue consisted a fresh issue of Rs 50 crore and offer for sale of 1.05 crore shares by promoters Edward Menezes and Sunil Chari.

Promoters and promoter group's shareholding in the company reduced to 72.69 percent post issue, from 95.06 percent earlier.

The company will utilise fresh issue proceeds for repayment/prepayment of certain indebtedness (including accrued interest) and funding working capital requirements, while it will not receive any funds from offer for sale.

Rossari manufactures majority of its products in-house from its Silvassa manufacturing facility which has an installed capacity of 1,20,000 MTPA. Now the company is currently setting up another manufacturing facility at Dahej in Gujarat with a proposed installed capacity of 1,32,500 MTPA which will enjoy proximity to the deep water, multi-cargo port of Dahej. The proposed state-of-the-art facility will be fully operational by March 2021.

Manufacturing of disinfectants & sanitizers as part of the Home, Personal Care & Performance Chemicals led the company's products to get categorized under essential goods, thus its manufacturing facility at Silvassa was not shut down during COVID-19 lockdown period.

Previously, company's business was much dependent on the textile space (nearly 71 percent revenue came from textile in FY18 which reduced to 44 percent in FY20), but steadily company has brought down the revenue share and simultaneously the revenue share of Home & Personal care division has increased and current it accounts nearly 47 percent of FY20 revenue, which turns a big positive for Rossari Biotech, said Ashika Stock Broking.

Company is financially sound company with low leverage in balance sheet. In past 3 years (FY17-FY20), company has delivered stupendous growth on revenue, EBITDA and net profit level, which grew at a CAGR of 42 percent, 57 percent and 60 percent respectively. Its robust growth was reflected in its return ratios with RoCE and RoNW of 25 percent and 32 percent in FY20.